Ollin Biosciences has announced important clinical trial results showing that OLN324, an investigational eye treatment, outperforms an existing therapy in treating two serious retinal diseases that threaten vision in millions of people worldwide. As reported by PharmaBiz.com, the final data from the JADE clinical study provides compelling evidence of OLN324’s potential to become a major advancement in ophthalmology.
Understanding the Diseases and the Treatment
Two conditions were evaluated in this study: diabetic macular edema (DME), which affects working-age adults with diabetes and is a leading cause of vision loss, and wet age-related macular degeneration (wAMD), which is the primary cause of vision loss in older adults. Both diseases involve abnormal blood vessel growth and leakage in the retina that damage vision.
OLN324 is a bispecific antibody, a type of protein therapy that simultaneously blocks two different disease-causing pathways: VEGF and Ang2. What makes OLN324 distinct is its enhanced potency against Ang2, a protein that contributes to vascular instability, inflammation, and scarring in the eye.
Superior Results in DME Patients
In patients with diabetic macular edema, OLN324 demonstrated notably stronger performance. The treatment produced faster and greater retinal drying compared to faricimab (Vabysmo), an existing VEGF/Ang2 inhibitor. Additionally, OLN324 achieved better vision improvements, and remarkably, 93% of DME patients treated with OLN324 4 mg completed 12 weeks after their last dose without requiring retreatment, compared to 89% of faricimab patients. This improved durability means patients would need fewer treatment injections, reducing both medical visits and treatment burden.
Strong Performance in wAMD Patients
For wet age-related macular degeneration, OLN324 matched faricimab in rapidly drying the retina but delivered superior vision gains. The vision advantage continued to grow after the intensive treatment phase, with OLN324 4 mg showing a 2.2-letter improvement over faricimab at the 20-week final visit. Like the DME findings, durability was comparable between treatments, with 82% of OLN324 patients completing 12 weeks without retreatment.
Breakthrough in a Difficult-to-Treat Problem
An exciting finding involves pigment epithelial detachments (PEDs), fluid-filled areas beneath the retina that occur in approximately 80% of wAMD patients and are particularly challenging to treat. OLN324 showed approximately 50% greater reduction in PED thickness compared to faricimab, and these improvements remained more durable through the 20-week follow-up period. This represents a meaningful advancement since persistent PEDs are associated with scarring and late vision loss.
Excellent Safety Profile
OLN324 demonstrated a favorable safety profile throughout the 20-week study. Notably, zero cases of intraocular inflammation occurred in OLN324-treated patients, compared to one case in the faricimab group. There were also no cases of retinal vasculitis or blood vessel occlusion with OLN324.
Looking Forward
The JADE trial enrolled 164 patients in the United States who received three monthly treatment doses followed by 12 weeks of observation. Based on these encouraging results, Ollin Biosciences plans to advance OLN324 into larger Phase 3 studies later in 2026, with anticipated enrollment across North America, South America, Europe, Japan, China, and South Korea. These results position OLN324 as a promising next-generation treatment option for two major causes of vision loss globally.
